FDA Authorizes First Wearable Device to Continuously Monitor Both Glucose and Ketone Levels

The U.S. Food and Drug Administration has authorized the world's first wearable device capable of continuously monitoring both blood sugar and ketone levels. The Libre Duo 10 Day system, developed by Abbott, represents a significant technological leap in diabetes care. By tracking two critical metabolic markers simultaneously, the biowearable aims to prevent diabetic ketoacidosis (DKA), a severe and potentially fatal complication that can develop rapidly when the body lacks sufficient insulin.[1][2]

The clearance marks the creation of an entirely new regulatory category. The FDA granted the device marketing authorization through its De Novo pathway, establishing the first "integrated continuous glucose and ketone monitoring" (iCGK) standard in the United States. The device is approved for people aged two and older living with diabetes, offering up to ten days of continuous wear on the back of the upper arm.[1][2]

For decades, managing diabetes has heavily focused on tracking glucose. However, when the body cannot absorb glucose due to a lack of insulin, it begins breaking down fat for energy. This metabolic shift produces chemicals called ketones. If ketone levels rise too high, the blood becomes dangerously acidic, triggering DKA. Hospital admissions for DKA have surged by 55 percent over the past decade, underscoring the need for better preventative tools.[2][3]

Until now, patients at risk of DKA had to rely on reactive, point-in-time testing methods. Standard urine strips or specialized blood meters provide a single snapshot of ketone levels, which cannot indicate whether those levels are actively climbing or falling. Because DKA can progress from early stages to a medical emergency within hours, these isolated readings often fail to provide enough warning for patients to intervene effectively.[1][3]

The new dual-sensor technology addresses this critical blind spot by measuring beta-hydroxybutyrate—the predominant ketone during DKA—directly in the interstitial fluid just beneath the skin. The device captures both glucose and ketone readings every minute, day and night. This data is transmitted wirelessly to a compatible smartphone app, which displays current levels, directional trend arrows, and automatic alerts if ketones cross a concerning threshold.[1][4]

Medical experts have likened the dual data streams to a car's dashboard. If continuous glucose readings act as the speedometer for daily diabetes management, the continuous ketone monitor functions as the check engine light. It operates quietly in the background, requiring no extra physical or mental effort from the user, but immediately flags when metabolic conditions begin to deteriorate.[2][5]

The ability to track ketones continuously is particularly crucial for specific patient populations. While people with Type 1 diabetes are inherently at higher risk for DKA, the device also offers a vital safety net for Type 2 diabetes patients who take sodium-glucose cotransporter 2 (SGLT2) inhibitors. These glucose-lowering medications provide significant cardiovascular and kidney benefits but carry a unique risk of inducing "euglycemic DKA."[5][6]

Euglycemic DKA is a deceptive complication where dangerous ketone accumulation occurs even while blood sugar levels appear perfectly normal or only mildly elevated. Because a standard continuous glucose monitor would show stable blood sugar, a patient might not realize they are in danger until severe symptoms like vomiting or abdominal pain set in. A dual-sensor system bridges this gap, catching the rising ketones that glucose readings alone would miss.[5][6]

The FDA's authorization was supported by robust clinical data from six studies involving more than 600 participants. The trials demonstrated that the wearable accurately tracked clinically meaningful differences in ketone levels across its full ten-day wear period. Crucially, the system successfully identified elevated ketones well before the clinical onset of DKA, validating its potential as an early warning system.[1][7]

The introduction of real-time ketone trends is expected to fundamentally shift how clinicians and pharmacists counsel patients. Instead of simply advising patients to check their ketones when they feel sick, healthcare providers can now teach them how to interpret trend arrows and respond to automatic alerts. This proactive approach allows for earlier hydration, insulin adjustments, and medical consultation before a hospital visit becomes necessary.[3][5]

Looking ahead, the dual-sensor technology is designed to integrate seamlessly into the broader digital health ecosystem. Abbott is actively working to connect the Libre Duo system with automated insulin delivery (AID) pumps. Compatibility with systems from Beta Bionics and Sequel Med Tech is anticipated by the end of the year, with integrations for Insulet and Tandem devices planned for 2027.[2][8]

By combining two essential metabolic metrics into a single, user-friendly wearable, the FDA's authorization represents a major milestone in patient safety. The technology not only reduces the daily burden of diabetes management but also provides families and caregivers with unprecedented peace of mind, knowing that a life-threatening emergency can be detected and diverted before it begins.[1][4]